

Amendments to the Claims:

Listing of Claims:


Claim 1 (original): A combination which comprises (a) a DNA topoisomerase inhibitor and (b) an IAP inhibitor, wherein the active ingredients are present in each case in free form or in the form of a pharmaceutically acceptable salt or any hydrate thereof, and optionally at least one pharmaceutically acceptable carrier; for simultaneous, separate or sequential use.

Claim 2 (original): A pharmaceutical composition comprising a quantity which is jointly therapeutically effective against a proliferative disease of a combination according to claim 1 and at least one pharmaceutically acceptable carrier.


Claim 3 (currently amended): ~~Use of a combination as defined in claim 1~~ A method for the treatment of a proliferative disease comprising administering a combination as defined in claim 1.

Claim 4 (canceled)

Claim 5 (currently amended): ~~Use A method~~ according to claims 3 or 4 wherein the IAP inhibitor is selected from compound C



and compound D



Claim 6 (currently amended): ~~Use A method~~ according to ~~any of claims 3 to 5~~ wherein the DNA topoisomerase inhibitor is a topoisomerase I inhibitor.

Claim 7 (currently amended): ~~Use A method~~ according to ~~any of claims 3 to 5~~ wherein the DNA topoisomerase inhibitor is a topoisomerase II inhibitor.

Claim 8 (original): A method of treating a proliferative disease in a patient, which comprises administering to the patient an effective combination of (a) a DNA topoisomerase inhibitor and (b) an IAP inhibitor.

Claim 9 (original): The method according to claim 8, which comprises administering to the patient an effective combination of (a) a topoisomerase I inhibitor and (b) an IAP inhibitor.

Claim 10 (original): A combined preparation, which comprises (a) one or more unit dosage forms of topoisomerase I inhibitor and (b) one or more unit dosage forms of an IAP inhibitor.

Claim 11 (original): The method according to claim 8, which comprises administering to the patient an effective combination of (a) a topoisomerase II inhibitor and (b) an IAP inhibitor.

Claim 12 (original): A combined preparation, which comprises (a) one or more unit dosage forms of topoisomerase II inhibitor and (b) one or more unit dosage forms of an IAP inhibitor.